Clinical trial · Interventional
Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients
NCT01015521CI-TRIAL-00004083withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was not initiated as planned
Summary
Brief summary (as posted)
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aminoflavone Prodrug | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Aminoflavone Prodrug
- description
- Aminoflavone to treat ER positive breast cancer patients
- interventionNames
- Drug: Aminoflavone Prodrug
- type
- EXPERIMENTAL
- label
- Aminoflavone Prodrug with pretreatment
- description
- Aminoflavone Prodrug to treat Triple Negative Breast Cancer
- interventionNames
- Drug: Aminoflavone Prodrug
Primary outcomes (1)
- measure
- Clinical Benefit Response
- timeFrame
- 6 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ER+ or TN Breast Cancer * Progression on an aromatase inhibitor if ER+ * Prior treatment with taxane if TN * 18 years or older * Adequate organ function * Measurable lesion Exclusion Criteria: * symptomatic pulmonary disease * brain metastases * pregnant females
References
Publications (1)
- DERIVEDSaito R, Miki Y, Hata S, Ishida T, Suzuki T, Ohuchi N, Sasano H. Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Res Treat. 2017 Feb;161(3):399-407. doi: 10.1007/s10549-016-4063-x. Epub 2016 Nov 30. PMID 27900579